Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649214 | 0.80 | CYP2C19 (0.34) | KDM4EMAPTAVPR1A | |
| SCHEMBL30968509 | 0.77 | — | — | |
| SCHEMBL13213504 | 0.77 | DRD2 (0.34) | DRD2DRD3 | |
| SCHEMBL16800667 | 0.77 | — | — | |
| SCHEMBL30968481 | 0.77 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL8997671 | 0.71 | HTR2C (0.33) | HTR2CMTNR1AMTNR1B | |
| SCHEMBL20231828 | 0.70 | ADRA2A (0.50) | DRD2DRD3DRD1POLB | |
| SCHEMBL5523900 | 0.70 | ADRA2A (0.50) | DRD2DRD3DRD1POLB | |
| SCHEMBL16799333 | 0.70 | DRD2 (0.36) | DRD2DRD3DRD1MAPT | |
| SCHEMBL5118608 | 0.69 | AVPR1A (0.33) | DRD2DRD3KDM4EMAPTAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232138-B | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-115232138-A | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2022-10-25 | — | — | CN | disclosed |
| WO-2015083130-A1 | FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-11 | — | — | WO | disclosed |
| WO-2009120774-A2 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. | 2009-10-01 | — | — | US | disclosed |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DHPS, CYP4Z1, CYP3A5 | DRD2 1299/4885DRD3 1648/4885DRD1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.